GLAXOSMITHKLINE PHARMACEUTICALS
|
The Current P/E Ratio of GLAXOSMITHKLINE PHARMACEUTICALS is 36.95.
| Share Price | ₹2,500.7 | Nov 05,2026 |
| Market Cap | ₹42,361.9 Cr | |
| Earnings-TTM | ₹1,146.5 Cr | TTM-Consolidated Results |
| Price/Earnings | 36.95x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of GLAXOSMITHKLINE PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹42,361.9 Cr] as on Nov 05,2026
(/) Earnings [ ₹1,146.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 36.95x ]
Thus, for GLAXOSMITHKLINE PHARMACEUTICALS , the investors are currently willing to pay 36.95 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of GLAXOSMITHKLINE PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of GLAXOSMITHKLINE PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of GLAXOSMITHKLINE PHARMACEUTICALS
PE Ratio Performance Analysis for GLAXOSMITHKLINE PHARMACEUTICALS
- GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 39.81x.
- GLAXOSMITHKLINE PHARMACEUTICALS 's operated at median p/e ratio of 37.34x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio peaked in Mar2024 at 55.8x.
- GLAXOSMITHKLINE PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2022 of 16.62x.
How does GLAXOSMITHKLINE PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| GLAXOSMITHKLINE PHARMACEUTICALS | 1,146.54 | 36.95 | 42,361.9 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,037.20 | 39.68 | 437,963.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 92.12 | 269,451.0 |
| TORRENT PHARMACEUTICALS LTD | 2,099.00 | 85.50 | 179,456.0 |
| CIPLA LTD | 2,868.29 | 39.48 | 113,246.0 |
| DR REDDYS LABORATORIES LTD | 2,759.70 | 41.19 | 113,664.0 |
| MANKIND PHARMA LTD | 2,249.69 | 46.18 | 103,881.0 |
| LUPIN LTD | 5,221.47 | 17.41 | 90,887.0 |
| ZYDUS LIFESCIENCES LTD | 4,159.00 | 28.69 | 119,341.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 27.71 | 102,895.0 |
| LAURUS LABS LTD | 1,333.75 | 95.00 | 126,703.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs GLAXOSMITHKLINE PHARMACEUTICALS 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.41x |
| Max industry PE | 95.00x |
| Median industry PE | 39.68x |
| Average industry PE | 49.99x |
You may also like the below Video Courses